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Topoisomerase poisons are chemotherapeutic agents that are used
extensively for treating human malignancies. These drugs can be
highly effective, yet tumors are frequently refractory to treatment
or become resistant upon tumor relapse. Using a pool-based RNAi
screening approach and a well characterized mouse model of
lymphoma, we explored the genetic basis for heterogeneous
responses to topoisomerase poisons in vitro and in vivo. These
experiments identified Top2A expression levels as major determi-
nants of response to the topoisomerase 2 poison doxorubicin and
showed that suppression of Top2A produces resistance to doxo-
rubicin in vitro and in vivo. Analogously, using a targeted RNAi
approach, we demonstrated that suppression of Top1 produces
resistance to the topoisomerase 1 poison camptothecin yet hyper-
sensitizes cancer cells to doxorubicin. Importantly, lymphomas
relapsing after treatment display spontaneous changes in topo-
isomerase levels as predicted by in vitro gene knockdown studies.
These results highlight the utility of pooled shRNA screens for
identifying genetic determinants of chemotherapy response and
suggest strategies for improving the effectiveness of topoisomer-
ase poisons in the clinic.
Chk2  doxorubicin  RNAi screen  Top1  Top2A
A myriad of genetic factors influence the efficacy of cancerchemotherapy, including both somatic changes in the tumor
itself as well as genetic polymorphisms present in the patient.
These factors include increased expression of detoxification
pumps that prevent access of the drug to its target (1), point
mutations that disrupt the drug–target interaction (2, 3), and
mutations in stress response pathways [e.g., p53 loss (4)]. To
tailor treatment successfully to the individual patient, a more
complete understanding of the genetic determinants of therapy
response is necessary.
RNA interference (RNAi) exploits a mechanism of gene
regulation whereby double-stranded RNAs are processed by a
conserved cellular machinery to suppress the expression of genes
containing homologous sequences (5). Importantly, libraries of
DNA-based vectors encoding short hairpin RNAs (shRNAs)
capable of targeting most genes in the human and mouse
genomes have been produced and enable forward genetic
screens to be performed in mammalian cells. Indeed, by using
human tumor-derived cell lines treated in vitro, RNAi has been
used to evaluate potential drug targets (6) or to investigate
mechanisms of drug action and drug resistance by screening for
new molecules that modulate the response of tumor-derived cell
lines to a given chemotherapeutic agent (7–10).
Here, we evaluate the suitability of combining mouse models
and RNAi to identify genetic modifiers of drug action in tumors
in their natural site. Initially, we chose to investigate resistance
to doxorubicin in the E-Myc mouse lymphoma system. Doxo-
rubicin (Adriamycin) is an anthracycline DNA-damaging agent
that exerts its effects primarily by targeting of the topoisomerase
2 activity and DNA intercalation (11). Along with etoposide and
the camptothecin derivatives, doxorubicin is one of several
topoisomerase-targeted drugs currently used as front-line ther-
apies for a wide variety of cancers. The E-Myc lymphoma
system has been a highly tractable model for studying the genetic
determinants of chemotherapeutic response in vivo in an immu-
nocompetent setting (12), and recently we have adapted RNAi-
based loss-of-function technology for use this model (13–15).
Here, we demonstrate that the E-Myc system can successfully
identify crucial mediators of the response to topoisomerase
poisons. These genes validate for relevance in vivo, suggesting
strategies for improved clinical use of these drugs.
Results
RNAi Screens Identify shRNAs Mediating Doxorubicin Resistance.
Because in vivo studies of drug sensitivity and resistance require
stable gene knockdown, we performed our initial in vitro screens
using retrovirally encoded shRNAs based on the MiR-30 mi-
croRNA (16). Importantly, these shRNAs can stably and effi-
ciently knockdown target genes when expressed at single copy in
the genome (13). We chose to survey shRNAs targeting the
‘‘cancer 1000,’’ a set of known or putative cancer-relevant genes
compiled by manual curation, microarray expression data, and
literature mining (17). To improve gene knockdown and facili-
tate in vivo experiments (13), all of the existing murine shRNAs
targeting the cancer 1000 set (2,300 shRNAs, two to three
shRNAs per gene) were cloned into a murine stem cell virus
(MSCV)-based vector that coexpressed green f luorescent
protein.
Our initial screens for shRNAs capable of conferring doxo-
rubicin resistance used p19ARF/;E-Myc lymphoma cells,
which retain the p53 tumor suppressor and an intact DNA
damage response (18, 19). shRNA pools were introduced into
lymphoma cells by retroviral transduction, and infected cultures
were treated with doxorubicin at doses that typically would kill
70–95% of cells in 24 h.
Three independent approaches were used to identify shRNAs
enriched after doxorubicin treatment [supporting information
(SI) Fig. S1]. Specifically, the library was screened by using either
(i) single treatments of lymphoma cells transduced with low-
complexity shRNA pools or, alternatively, (ii) single or (iii) serial
treatments of lymphoma cells transduced with the whole shRNA
set. Standard DNA sequencing of amplified provirus shRNAs
was used to identify constituent shRNAs and to determine their
relative representation in the treated and untreated cell popu-
lations (Fig. S2). Similar results were also produced by using
high-throughput shRNA deconvolution via DNA microarrays
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and Solexa deep sequencing, illustrating the potential for pooled
screens of expanded scope (D.L.B., S.W.L., J. Zuber, and E.
Hodges, unpublished work). Irrespective of the screening ap-
proach, shRNAs targeting p53, Chk2, and Top2A (two indepen-
dent shRNAs) were repeatedly identified as being enriched upon
doxorubicin treatment. Additional shRNAs were also identified
as becoming enriched after drug treatment via one strategy or
another (Fig. S2), and these should be the subject of future
studies.
To validate the screening results, we retested the major
shRNA hits in an ‘‘in vitro competition assay.’’ This assay
examines the impact of specific shRNAs on therapy response in
partially transduced cell populations, using GFP-based flow
cytometry to track the survival advantage or disadvantage
conferred by specific shRNAs (Fig. 1A). shRNAs targeting p53,
Chk2, and Top2A successfully validated in the competition assay:
the shRNAs were dramatically enriched in cell populations
within 24 h after doxorubicin treatment (Fig. 1B). Additionally,
these shRNAs effectively suppressed expression of their in-
tended target (Fig. 1C).
p53 and Chk2 are key components of DNA damage response
pathways and, indeed, p53 loss confers resistance to doxorubicin
in the E-Myc transgenic model (13, 20). Importantly, multiple
shRNAs targeting Chk2 promoted doxorubicin resistance, sug-
gesting that the effects of these shRNAs were ‘‘on target,’’ i.e.,
specifically due to Chk2 gene knockdown (Fig. 1B and Fig. S3).
Although Chk2 can sensitize cells to DNA-damaging agents in
some contexts (21, 22), our results are consistent with a role for
Chk2 in signaling p53-dependent apoptosis in lymphoid cells (20,
23). These results suggest we can identify relevant mediators of
drug resistance using pool-based RNAi screening approaches.
Top2A shRNAs Cause Resistance Specifically to Topoisomerase 2
Poisons. shRNAs targeting Topoisomerase 2 (Top2A) were the
most frequently recovered shRNAs from doxorubicin-treated
cells, with at least two independent shRNAs isolated per screen.
Top2A is a target of the drug doxorubicin (11) and is an essential
gene in mammals (24). Unlike typical enzyme inhibitors where
knockdown of the drug target would be expected to mimic drug
action and promote cell death, doxorubicin is a topoisomerase
poison that stabilizes the cleavable complex consisting of double-
stranded DNA breaks to which the enzyme is covalently at-
tached. Doxorubicin therefore causes excessive double-stranded
DNA breaks via unresolved cleavable complexes in a topoi-
somerase-dependent manner, thereby explaining how Top2A
down-regulation might confer doxorubicin resistance (25). Re-
markably, even very potent knockdown of Top2A (Fig. 1C) had
little, if any, impact on cell proliferation in the absence of drug
treatment, suggesting that normal cell proliferation can proceed
with relatively low Top2A expression (data not shown).
Although previous work has suggested a relationship between
Top2A levels and doxorubicin sensitivity (26), the effect has not
been studied extensively or validated in vivo. The effects of
Top2A knockdown were specific to topoisomerase 2 poisons:
shTop2A caused resistance to another, structurally unrelated
TOP2A poison, etoposide, but not to the alkylating agent
maphosphamide (an active metabolite of cyclophosphamide)
nor the topoisomerase 1 poison camptothecin (Fig. 2A). In
contrast, an shRNA targeting p53 caused cross-resistance to
these different agents (Fig. 2B). The drug response-modifying
effects of Top2A knockdown were likely ‘‘on target’’: four of four
Top2A shRNAs mediated resistance specifically to topoisomer-
ase 2 poisons (Fig. 2C and Fig. S4 A and C). As expected, cells
with reduced TOP2A levels displayed a diminished DNA dam-
age signal and response, as shown by lower -H2AX signal, less
p53 stabilization, and less apoptosis upon doxorubicin treatment
(Fig. 2D and Fig. S5). Accordingly, the ability of Top2A shRNAs
to promote doxorubicin resistance was attenuated in p53-null
E-Myc lymphoma cells (Fig. S4B), although clearly some signals
downstream of chemotherapy-induced DNA damage are p53-
independent (27).
Top2A shRNAs Confer Resistance to Doxorubicin in Vivo. To test the
role of Top2A in doxorubicin resistance in vivo, E-Myc;Arf/
lymphoma cells were infected in vitro with shTop2A or a control
vector and transplanted via tail vein injection into multiple
syngeneic recipient mice. Tumor-bearing recipient mice were
then treated with the maximum tolerated dose of doxorubicin
(Fig. S6). Top2A knockdown caused doxorubicin resistance in
vivo as measured by an in vivo competition assay (an increase in
the percentage of GFP-positive cells after drug treatment; Fig.
3A) and reduced tumor-free (Fig. 3B) and overall survival (data
Fig. 1. A rapid RNAi enrichment screen identifies mediators of doxorubicin
resistance. (A) The GFP competition assay. Differential survival of shRNA-
transduced cells (green) relative to control cells (colorless) is assayed by
changes in the percentage GFP in the surviving cell population. (B) GFP
competition assay data from lymphoma cells infected with the indicated
shRNA either untreated or 24 h after doxorubicin (DXR) treatment at the
indicated doses. (C) Immunoblotting of lysates from lymphoma cells trans-
duced with shRNAs targeting p53, Chk2, and Top2A either untreated or
treated for 8 h with 31 ng/ml doxorubicin to stabilize p53. Tubulin serves as a
loading control.
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not shown). These results demonstrate that reduced Top2A
expression is a bona fide mechanism of drug resistance in vivo.
Top1 shRNAs Confer Resistance to Topoisomerase 1 Poisons in Vitro
and in Vivo. TOP2A is not the only topoisomerase targeted by
front-line anticancer therapeutics. Topoisomerase 1 (TOP1) is
the target of camptothecin (28, 29) and its derivatives irinotecan
(Camptosar/CPT-11) and topotecan (Hycamtin). TOP1-
deficient yeast are viable and resistant to camptothecin (30), but
complete knockout of Top1, like Top2A, is lethal in mammals
(31). Prompted by our studies on doxorubicin and Top2A, we
tested whether Top1 knockdown could induce camptothecin
resistance in cancer cells. Indeed, Top1 knockdown in E-
Myc;Arf/ lymphomas caused resistance specifically to camp-
tothecin (Fig. 4A), and the effects were reproducible by using
multiple independent Top1 shRNAs (Fig. 4B, Fig. S7, and Fig.
S8). Even modest Top1 knockdown achieved this cytoprotective
effect (Fig. 4C). Importantly, this effect was also seen in human
cells expressing a TOP1 shRNA (Fig. S8C).
p53 induction was compromised in shTop1-expressing lym-
Fig. 2. Suppression of Top2A expression causes resistance to topoisomerase 2 poisons in vitro. (A and B) Flow cytometric analyses of lymphoma cells expressing
shTop2A 668 (A) or shp53 1224 (B) after 24 h of the indicated drug treatments. DXR, doxorubicin; ETOP, etoposide; MAF, maphosphamide; CPT, camptothecin. (C)
Lymphoma cells, transduced singly with four independent Top2A shRNAs, were puromycin-selected and treated with doxorubicin for 24 h at the indicated doses.
Viability was assayed by flow cytometry (FSC versus SSC) and plotted relative to untreated controls. Error bars areSEM from three replicates. (D) Immunoblotting of
lymphoma cell lysates expressing no short hairpin (Vector) or Top1, Top2A, or p53 shRNAs in the presence or absence of doxorubicin (DXR; 15.6 ng/ml for 8 h).
Fig. 3. Top2A knockdown causes doxorubicin resistance in vivo. In vivo competition assay is shown. (A) GFP flow cytometry plots. Lymphoma cells were infected
in vitro with GFP-tagged shTop2A 668 or 849, shp53, or vector control constructs (A Left). These cells were injected into the tail vein of syngeneic recipient mice
(five mice per cohort) and were monitored daily for tumors by palpation. Upon tumor onset (day 0), one mouse from each cohort was killed, and lymphoma cells
were assayed for percentage GFP (A Middle). The remaining mice were treated with doxorubicin (10 mg/kg i.p. injection), and tumors were harvested upon
relapse and assayed for percentage GFP (A Right). (B) Kaplan–Meier tumor-free survival curves. Vector, shTop2A, and shp53 tumors were FACS-sorted to 100%
GFP before injection into recipient mice and DXR-treated as for A at day 0.
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phoma cells treated with camptothecin, suggesting that these
cells mounted a weaker DNA damage response (Fig. 4C).
Accordingly, resistance was also attenuated in an E-
Myc;p53/ background (Fig. S7B). Mice harboring shTop1-
expressing lymphomas displayed a reduced tumor-free survival
compared with controls after treatment with irinotecan, indi-
cating that reduced Top1 expression promotes resistance to
topoisomerase 1 poisons in vivo (Fig. 4D). Therefore, sufficient
expression of Top2A or Top1 is required to achieve a potent
response to chemotherapeutic agents targeting each particular
topoisomerase.
Top1 shRNAs Enhance Sensitivity to Topoisomerase 2 Poisons. The
drug resistance phenotypes conferred by Top1 shRNAs were
specific for topoisomerase 1 poisons. For example, Top1 knock-
down had little effect on tumor cell sensitivity to the alkylating
agent maphosphamide (Fig. 4A). Unexpectedly, Top1 knock-
down hypersensitized cells to the topoisomerase 2 poisons
doxorubicin and etoposide (Fig. 4A), an effect reproduced with
nine independent Top1 shRNAs (Fig. S7 and Fig. S8). Further-
more, mice harboring transplanted lymphomas expressing Top1
shRNAs showed an improved tumor-free survival compared
with controls after irinotecan treatment (Fig. 5A). Therefore, in
this tumor model, suppression of Top1 synergizes with topo-
isomerase 2 poisoning by chemotherapeutic agents.
Spontaneous Changes in Topoisomerase Levels Accompany Relapse
After Doxorubicin Therapy. To examine the relevance of topoisom-
erase status to resistance mechanisms spontaneously occurring in
treated lymphomas, primary tumors and postdoxorubicin treat-
ment relapses from Fig. 5A were analyzed for Top1 and Top2A
expression levels (Fig. 5B). The relevance of Top2A levels to the
emergence of tumor relapses was supported by the fact that half of
the relapsed tumors displayed dramatically reduced Top2A levels
(one of two control tumors and two of four shTop1-expressing
tumors) without experimental manipulation via Top2A shRNAs.
As further evidence that Top1 knockdown can sensitize to the
topoisomerase 2 poison doxorubicin, one shTop1 relapse (relapse
3) recovered expression of Top1 to approximately wild-type levels.
Relapsed tumors treated ex vivo showed resistance to doxorubicin,
but not cisplatin, suggesting that the resistance mechanisms were
topoisomerase-specific (Fig. S9). Together, these results indicate
that although alterations in topoisomerase expression levels repre-
sent one of undoubtedly many therapy resistance mechanisms,
these changes can play a substantial role in chemotherapy response
in vivo.
Discussion
In this study we document the utility of combining RNAi screens
with mouse cancer models to identify and characterize molecular
determinants of therapeutic response that are relevant to treat-
ment outcome in vivo. This approach is ideal for rapid in vivo
validation of candidate genes and may serve as a relevant setting
for conducting in vivo RNAi-based screens for genetic determi-
nants of drug resistance. Such methodology is easily extendable
to other chemotherapeutics and tumor systems to allow a more
global view of therapy response mediators, including their
context-dependence across different tumor and host genotypes.
The mechanism whereby Top1 and Top2A down-regulation
produces resistance to their cognate poisons is probably due to
a reduction in topoisomerase–DNA cleavage complexes, result-
ing in less DNA damage (see Figs. 2D and 4C; ref. 32). By
contrast, the mechanism whereby Top1 down-regulation hyper-
sensitizes to topoisomerase 2 poisons remains to be precisely
Fig. 4. Top1 knockdown causes camptothecin resistance in vitro and in vivo. (A) Top1 knockdown causes resistance to camptothecin but hypersensitizes to the
topoisomerase 2 poisons, doxorubicin and etoposide, as shown by a GFP competition assay 24 h after drug treatment. (B) In vitro viability assays of puromycin-selected
(shRNA-containing) cells for four independent shRNAs targeting Top1, after 24-h camptothecin treatment. Error bars are SEM from three replicates. (C) Immuno-
blotting of E-Myc;Arf/ lymphoma cell lysates with or without camptothecin (31 nM CPT, 8 h). (D) Kaplan–Meier survival curve. E-Myc;Arf/ lymphomas were
infected in vitrowith vector control or shTop1 2215 and were FACS-sorted to 100% GFPbefore injection into recipient mice. Upon lymphoma onset (day 0) mice were
treated with irinotecan (CPT-11), a clinically relevant camptothecin derivative (50 mg/kg intraperitoneal injection daily for 2 days) and monitored for survival.
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determined. However, this effect is not simply due to a com-
pensatory up-regulation of Top2A because Top2A levels did not
increase in response to Top1 knockdown in our system (Figs. 2D
and 4C). Studies in yeast suggest that an overall amount of
topoisomerase activity may be required for cell viability because
topoisomerase I/II double mutants exhibit more serious defects
in DNA unwinding, chromatin structure, and cell cycle progres-
sion compared with either single mutant (33, 34). If so, thera-
peutic poisoning of Top2Awith simultaneous down-regulation of
Top1 could cause cellular topoisomerase activity to fall below
this crucial threshold, triggering cell death. Consistent with this
model, shTop1 lymphoma cells treated with doxorubicin show an
impaired progression through S phase compared with control
cells (Fig. S10).
The relative importance of various mechanisms to clinical drug
resistance is an area of active debate. In some settings efflux pump
overexpression may predominate (35), whereas in other settings,
blocked apoptosis or senescence may be largely responsible for
resistance (18, 36). Our studies using RNAi in vivo, together with
our observation that relapsed tumors frequently display altered
topoisomerase levels compared with the parental tumor, suggest
that topoisomerase expression levels are relevant determinants of
therapeutic response. In fact, TOP2A amplification [linked to the
ERBB2 locus and thus common in human breast cancer (37)]
predicts a favorable response to anthracycline therapy, if ERBB2
status is appropriately controlled for (38). Surprisingly, hemizygous
deletion of TOP2A is also common in breast cancer (39), and our
results suggest that patients with such deletions in TOP2A may be
less responsive to doxorubicin therapy, a possibility that is readily
testable.
Similarly, TOP1 levels may also influence the response to
topoisomerase poisons and thus serve as a useful biomarker to
guide the use of these agents in the clinic. The TOP1 gene is
located on chromosome 20q12, a locus that is often amplified in
colon carcinoma (40). The enhanced sensitivity to these drugs
predicted to arise from higher TOP1 levels may explain, in part,
why topoisomerase 1 poisons are a mainstay therapy for this
disease. In contrast, hemizygous deletion of chromosome 20q12
is observed in a subset of acute myeloid leukemia samples [M.
Spector, Cold Spring Harbor Laboratory (CSHL), personal
communication], a leukemia where patients are typically treated
with doxorubicin plus cytarabine. Consistent with our work, 20q
deletions, when found as the sole chromosomal aberration, are
associated with a more favorable clinical outcome (41). Al-
thoughmore detailed functional and clinical studies remain to be
performed, our results highlight the potential of combining
RNAi and in vivomouse models to identify potential therapeutic
targets as well as biomarkers for predicting treatment response.
Materials and Methods
Short Hairpin RNA Vectors. A MiR-30-based shRNA library (16) targeting the
cancer 1000 gene set (2,300 shRNAs) was subcloned into LTR-driven MiR30
Puro-IRES-GFP (LMP) and LTR-driven MiR30 SV40-GFP (LMS) (MSCV-based
vectors) (13) in pools of 96 or 48 shRNAs, respectively. Individual shRNA
constructs were generated as described previously. Targeting sequences were
selected based on RNAi Codex algorithms (16) or BIOPREDsi design (42) and
are available upon request.
RNAi Screens. Lymphoma cells were cultured and infected as described pre-
viously. E-Myc;Arf/ lymphoma cells, 2 days after infection with shRNA
libraries (infected to 30%), were treated for 24 h with 7.8 ng/ml and 15.6
ng/ml doxorubicin for lenient and stringent selection conditions, respectively.
Ninety percent of the culture was removed and replaced with fresh B cell
medium on day 2 and day 5 after infection to allow recovery and proliferation
of surviving cells. Final samples were taken on day 8 for GFP competition
assay/shRNA representation determination. Pool-by-pool screens (Fig. S1A)
were performed in a 12-well format by using500,000 cells per experimental
condition (pool sizes 96 or 48 shRNAs). The single treatment, whole cancer
1000 library screen (Fig. S1B), was performed in six biological replicates, using
1 million live, infected cells per treatment. Serial enrichment screening (Fig.
S1C) was performed by infecting 1  107 cells with the entire cancer 1000
shRNA library to a final infection rate of 20%. Unsorted populations of
infected cells were treated for 24 h with 7.8 ng/ml doxorubicin and then
surviving cells were allowed to regrow for 4 days in fresh medium. shRNAs
from GFP-sorted surviving cells were recloned into the LMS parent vector and
used to infect naı¨ve lymphoma cells. This process was repeated until GFP
enrichment was detectable acutely (at 24 h) after doxorubicin treatment. This
occurred consistently after three rounds of treatment.
To identify constituent shRNAs, genomic shRNA integrants were PCR-
amplified and subcloned into the LMP vector. Constituent shRNAs were identi-
fied by using the MSCV-specific 5 primer, CCCTTGAACCTCCTCGTTCGACC.
Immunoblotting. Western blotting was performed as described in ref. 13.
Proteins were detected by using the following antibodies: anti-p53 (clone 505,
1:500; Novacastra); anti-CHK2 (clone 151-176, in-house monoclonal, 1:100);
anti-TOP1 (human scleroderma serum, 1:1,000; Topogen); anti-TOP2A (rabbit
polyclonal, 1:1,000; Topogen); anti-H2AX (monoclonal clone JBW301,
1:1000; Upstate/Millipore); and anti-tubulin (B5-1-2, 1:5,000; Sigma). Second-
ary antibodies were horseradish peroxidase-conjugated anti-mouse/rabbit/
human IgG (GE Healthcare; 1:5,000). p53 was stabilized by using 31 ng/ml
doxorubicin for 8 h (Fig. 1C), 16 ng/ml doxorubicin for 8 h (Fig. 2D), or 31 nM
camptothecin for 8 h (Fig. 4C).
Competition and Viability Assays. Two days after infection, lymphoma cells were
split into replicate wells of500,000 cells in 12-well plates. After 24-h treatments
with a range of drug doses, the GFP-positive percentage was quantified in the
surviving cell population by using a BD Biosciences LSRII flow cytometer. The live
cell population was gated via a forward scatter (FSC) versus side scatter (SSC)
plotting. For in vivo competition assays, lymphoma cells were infected in vitro, as
described above. Lymphoma cells, GFP FACS sorted or unsorted, as indicated,
were tail vein-injected into syngeneic recipient mice. Upon tumor onset (day 0),
mice were treated with doxorubicin (10 mg/kg intraperitoneal injection) or
irinotecan (CPT-11, 50 mg/kg intraperitoneal injection, daily for 2 days) and
monitored for overall survival and tumor-free survival. Isolation of lymphomas
for the GFP competition assay was carried out as described (13, 36). For invitro cell
Fig. 5. Top1 knockdown can sensitize to doxorubicin treatment in vivo. (A)
Top1 knockdown sensitizes E-Myc;Arf/ lymphomas to doxorubicin in vivo, as
shownbyanincreased invivo tumor-freesurvivalafterdoxorubicintreatment (10
mg/kg, day 0). shTop1 data are pooled from four shTop1 1600 and four shTop1
2215 mice. (B) Predicted changes in topoisomerase expression levels occur spon-
taneouslyduringtreatment failure invivo. Immunoblottinganalysisofuntreated
lymphomas and postdoxorubicin-treated relapses from A.
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viability assays, lymphoma cells were treated in triplicate at the indicated doses of
doxorubicin/camptothecin. Viability was determined after 24 h by an FSC versus
SSC gate and plotted relative to untreated viability.
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